pharmaphorum23h
AbbVie launches pump-based Parkinson’s drug in EU
AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...
pharmaphorum23h
A history of Bristol-Myers Squibb
Around the same time, the prototype of the Squibb logo was designed ... Biopharmaceuticals and a neuropathic pain agreement with Allergan. On May 4th 2010, Lamberto Andreotti became BMS' CEO ...
gut.bmj18h
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
Objective Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn’s disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported. Results 247 ...